title: Bioconversion of ginsenoside rb1 into compound k by Leuconostoc citreum LH1 isolated from kimchi.
abstract: About 40 different types of ginsenoside (ginseng saponin), a major pharmacological component of ginseng, have been identified along with their physiological activities. Among these, compound K has been reported to prevent the development of and the metastasis of cancer by blocking the formation of tumors and suppressing the invasion of cancerous cells. In this study, ginsenoside Rb1 was converted into compound K via interaction with the enzyme secreted by β-glucosidase active bacteria, Leuconostoc citreum LH1, extracted from kimchi. The optimum time for the conversion of Rb1 to compound K was about 72 hrs at a constant pH of 6.0 and an optimum temperature of about 30°C. Under optimal conditions, ginsenoside Rb1 was decomposed and converted into compound K by 72 hrs post-reaction (99%). Both TLC and HPLC were used to analyze the enzymatic reaction. Ginsenoside Rb1 was consecutively converted to ginsenoside Rd, F2, and compound K via the hydrolyses of 20-C β-(1 → 6)-glucoside, 3-C β-(1 → 2)-glucoside, and 3-C β-glucose of ginsenoside Rb1.
authors.affiliation: Dept. of Oriental Medicinal Material & Processing, College of Life Science, Korean Ginseng Center Most Valuable Product and Ginseng Genetic Resource Bank, Kyung Hee University , Yongin 446-701 , Korea.
authors.forename: Lin-Hu
authors.initials: LH
authors.lastname: Quan
authors.forename: Jin-Ying
authors.initials: JY
authors.lastname: Piao
authors.forename: Jin-Woo
authors.initials: JW
authors.lastname: Min
authors.forename: Dong-Uk
authors.initials: DU
authors.lastname: Yang
authors.forename: Hee Nyeong
authors.initials: HN
authors.lastname: Lee
authors.forename: Deok Chun
authors.initials: DC
authors.lastname: Yang
keywords: Leuconostoc citreum LH1; bioconversion; compound K; ginsenoside Rb1
references.citation: Biotechnol Lett. 2003 Feb;25(4):339-44
references.pmid: 12882549
references.citation: Yao Xue Xue Bao. 1994;29(11):801-8
references.pmid: 7863780
references.citation: Yakugaku Zasshi. 1994 Aug;114(8):550-64
references.pmid: 7932100
references.citation: Biochim Biophys Acta. 1975 Feb 19;377(2):410-20
references.pmid: 235305
references.citation: Zhongguo Zhong Yao Za Zhi. 1997 Mar;22(3):174-6, 192
references.pmid: 10743189
references.citation: Planta Med. 2003 Mar;69(3):285-6
references.pmid: 12677539
references.citation: Biol Pharm Bull. 2002 Jan;25(1):58-63
references.pmid: 11824558
references.citation: Planta Med. 1982 Mar;44(3):146-9
references.pmid: 17402098
references.citation: Biotechnol Lett. 2006 Jul;28(14):1121-7
references.pmid: 16788737
references.citation: Tetrahedron Lett. 1965 Jan;42:207-13
references.pmid: 14252492
references.citation: Biosci Biotechnol Biochem. 2001 May;65(5):1163-9
references.pmid: 11440132
references.citation: J Tradit Chin Med. 1988 Dec;8(4):293-5
references.pmid: 3246891
references.citation: Biochem Biophys Res Commun. 1992 Dec 15;189(2):670-6
references.pmid: 1472038
references.citation: Chem Pharm Bull (Tokyo). 1991 Feb;39(2):400-4
references.pmid: 2054864
references.citation: J Tradit Chin Med. 1983 Jun;3(2):89-94
references.pmid: 6555453
references.citation: J Asian Nat Prod Res. 2006 Sep;8(6):519-27
references.pmid: 16931427
references.citation: Anticancer Drugs. 1991 Feb;2(1):63-7
references.pmid: 1958854
references.citation: Neurochem Int. 1992 Jul;21(1):1-5
references.pmid: 1338897
references.citation: Drug Metab Dispos. 2003 Aug;31(8):1065-71
references.pmid: 12867496
references.citation: J Ethnopharmacol. 2003 Feb;84(2-3):187-92
references.pmid: 12648814
references.citation: Planta Med. 1984 Dec;50(6):462-5
references.pmid: 6531406
references.citation: Biol Pharm Bull. 2000 Dec;23(12):1481-5
references.pmid: 11145182